Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
My No.1 investing mistake to avoid
Motley Fool Take Stock
Big banks were 'sorry', but not much has changed
Healthcare Shares
Macquarie Group picks the 3 best healthcare stocks for 2019
Growth Shares
3 quality ASX shares for growth investors to buy today
Share Market News
This GDP data chart shows how the Australian economy is edging towards recession
Share Market News
Top brokers name 3 ASX shares to buy today
Share Gainers
ALL ORDINARIES finishes lower Tuesday: 8 shares you missed
Share Gainers
Cochlear has "head in the sand" over A$378 million legal bill
Share Market News
ASX 200 lunch time report: Ausdrill, Coles, & Galaxy lower
Share Gainers
Top broker slaps buy rating on Cochlear shares
Share Gainers
Why the CSL share price is touching $200 again
Share Gainers
Profit report: Why the Nanosonics share price just printed a record high
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
